Journal of Radioanalytical and Nuclear Chemistry

, Volume 298, Issue 3, pp 2025–2028 | Cite as

Tritiation of two potent catecholamine beta-adrenergic receptor agonists

  • David G. Ahern
  • Demetri Orphanos
  • Crist N. Filer


The tritiation of the beta-adrenergic catecholamines isoproterenol and hydroxybenzylisoproterenol is described.


Beta-adrenergic Tritium Tritium NMR 



We would like to acknowledge the contribution of Dr. Puliyer Srinivasan of PerkinElmer Life Sciences & Technology in obtaining the NMR spectra.


  1. 1.
    Wachter SB, Gilbert EM (2012) Beta-adrenergic receptors, from their discovery and characterization through their manipulation to beneficial clinical application. Cardiology 122:104–112CrossRefGoogle Scholar
  2. 2.
    Port DJ (2012) Beta-adrenergic signaling: complexities and therapeutic relevance to heart failure. Curr Signal Transduct Ther 7:120–131CrossRefGoogle Scholar
  3. 3.
    Yu J-T, Wang N-D, Ma T, Jiang H, Guan J, Tan L (2011) Roles of beta-adrenergic receptors in Alzheimer’s disease: implications for novel therapeutics. Brain Res Bull 84:111–117CrossRefGoogle Scholar
  4. 4.
    Wang D, Xiang YK (2011) Beta-adrenergic receptor, amyloid beta peptide, and Alzheimer’s disease. Curr Top Membr 67:205–228CrossRefGoogle Scholar
  5. 5.
    Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18:1201–1206CrossRefGoogle Scholar
  6. 6.
    Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Diz PG, Rey JMG, Garcia-Garcia A (2010) Beta-adrenergic receptors in cancer: therapeutic implications. Oncol Res 19:45–54CrossRefGoogle Scholar
  7. 7.
    Filer CN, Ahern DG, Granchelli FE, Neumeyer JL, Law S-J (1980) Aporphines 28. Preparation of (–)-N-n-[3H- and-2H] propylnorapomorphine. J Org Chem 45:3465–3467CrossRefGoogle Scholar
  8. 8.
    Filer CN, Ahern DG (1980) Preparation of (–)-[8,9-3H] apomorphine at high specific activity. J Org Chem 45:3918–3919CrossRefGoogle Scholar
  9. 9.
    Orphanos D, Filer CN (2002) The preparation of dopaminergic agonist [5,8-3H] (±)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene at high specific activity. J Radioanal Nucl Chem 254:223–224CrossRefGoogle Scholar
  10. 10.
    Filer CN, Orphanos D, Seguin RJ (2006) Synthesis of [ring-3H] dopamine and fluoro analogues at high specific activity. Synth Commun 36:975–978CrossRefGoogle Scholar
  11. 11.
    Ahern DG, Laseter AG, Filer CN (2003) The synthesis and characterization of [2,3-3H] gamma-aminobutyric acid via 4-aminotetrolic acid at high specific activity. Appl Radiat Isot 58:477–479CrossRefGoogle Scholar
  12. 12.
    Filer CN, Ahern DG (1987) The preparation and characterization of [3H] histamine dihydrochloride at high specific activity. J Label Compd Radiopharm 24:615–622CrossRefGoogle Scholar
  13. 13.
    Ahern DG, Morrison JC, Filer CN (2009) Tritiation of melatonin by several methods. J Radioanal Nucl Chem 279:3–6CrossRefGoogle Scholar
  14. 14.
    Ahern DG, Egan JA, Nugent RP, Filer CN (2013) Synthesis of some 6-keto morphinan mu opiate receptor agonists labelled with tritium at high specific activity. J Radioanal Nucl Chem 295:1029–1031CrossRefGoogle Scholar
  15. 15.
    Ahern DG, Seguin RJ, Filer CN (2004) Serotonin receptor agonists buspirone and (±)-DOB: tritiation at high specific activity. J Radioanal Nucl Chem 261:465–467CrossRefGoogle Scholar
  16. 16.
    Ahern DG, Seguin RJ, Filer CN (2012) High specific activity tritium labelling of some sigma-1 receptor agonists. J Radioanal Nucl Chem 292:19–23CrossRefGoogle Scholar
  17. 17.
    Ahern DG, Orphanos D, Filer CN (2012) Trace amine receptor ligands: tritiation at high specific activity. J Radioanal Nucl Chem 293:415–418CrossRefGoogle Scholar
  18. 18.
    Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnoli P (2012) Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 53:2181–2192CrossRefGoogle Scholar
  19. 19.
    Pagadala J, Williams-Guy K, Nooh MM, Steinle JJ, Miller DD (2011) Beta-adrenergic receptor signaling by the isomers of isoproterenol and like drugs in retinal endothelial cells and Mueller cells. Med Chem Commun 2:726–730CrossRefGoogle Scholar
  20. 20.
    Jiang Y, Walker RJ, Kern TS, Steinle JJ (2010) Application of isoproterenol inhibits diabetic-like changes in the rat retina. Exp Eye Res 91:171–179CrossRefGoogle Scholar
  21. 21.
    Blair LK, Baldwin J, Smith WC (1977) Halogen-amine complexes in chemical synthesis. 1. The oxidation of alcohols by 1,4-diazabicyclo[2.2.2]octane. 2Br2 complex. J Org Chem 42:1816–1817CrossRefGoogle Scholar
  22. 22.
    Aukett P, Barker IRL (1972) The kinetics and mechanism of the oxidation of benzyl alcohol to benzaldehyde by bromine. J Chem Soc Perkin Trans II:568–572Google Scholar
  23. 23.
    Filer CN (2010) Direct metal-catalyzed tritiation of organic compounds. J Label Compd Radiopharm 53:739–744CrossRefGoogle Scholar
  24. 24.
    Lefkowitz RJ, Williams LT (1977) Catecholamine binding to the beta-adrenergic receptor. Proc Natl Acad Sci 74:515–519CrossRefGoogle Scholar
  25. 25.
    Moed HD, Van Dijk J, Niewind H (1955) Synthesis of beta-phenylethylamine derivatives. III Bronchodilators. Rec Trav Chim 74:919–936CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2013

Authors and Affiliations

  • David G. Ahern
    • 1
  • Demetri Orphanos
    • 1
  • Crist N. Filer
    • 1
  1. 1.PerkinElmer Life Sciences & Technology, Inc.WalthamUSA

Personalised recommendations